Antinociceptive interactions of triple and quadruple combinations of endogenous ligands at the spinal level.
A very interesting and rapidly developing field of pain research is related to the roles of different endogenous ligands. This study determined the antinociceptive interactions of triple and quadruple combinations of different endogenous ligands (endomorphin-1, adenosine, agmatine and kynurenic acid) on carrageenan-induced inflammatory pain model at the spinal level. Intrathecal infusion (60 min) of these drugs alone, in double, triple or quadruple combinations, was followed by a 60-min observation period. During the infusion, antihyperalgesic effect of 0.3 microg/min endomorphin-1 was higher in the triple combinations than those in the double combinations. After cessation of drug administration, only the combination of 0.3 microg/min endomorphin-1, 1 microg/min agmatine, and 0.3 microg/min adenosine was more effective than the double combinations. In quadruple combinations, the antinociceptive effects of both 0.1 and 0.3 microg/min endomorphin-1 were significantly potentiated by the otherwise ineffective triple combination of adenosine, agmatine, and kynurenic acid. No side effects could be observed at these doses. These results demonstrate that triple and quadruple combinations of these endogenous ligands caused more effective antihyperalgesia compared with double combinations. Accordingly, the doses of these substances could be further reduced, thus, reinforcing the view that complex activation and/or inhibition of different systems can be sufficiently effective in blocking nociception without adverse effects. Because all of these drugs had effects on various receptors and systems, the possible types of these interactions were discussed.
Horvath
Gyongyi
G
Department of Physiology, Faculty of Medicine, University of Szeged, Szeged, Hungary. horvath@phys.szote.u-szeged.hu
Kekesi
Gabriella
G
Tuboly
Gabor
G
Benedek
Gyorgy
G
D000241:Adenosine / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D000376:Agmatine / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D000700:Analgesics / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D000818:Animals; D019540:Area Under Curve; D004195:Disease Models, Animal; D004338:Drug Combinations; D007278:Injections, Spinal; D007736:Kynurenic Acid / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D008024:Ligands; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009842:Oligopeptides / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D010146:Pain; D051381:Rats; D017208:Rats, Wistar; D043562:Receptors, G-Protein-Coupled / Q000187:drug effects / Q000502:physiology; D017450:Receptors, Opioid, mu / Q000187:drug effects / Q000502:physiology; D013116:Spinal Cord / Q000187:drug effects / Q000502:physiology* / Q000503:physiopathology
D000700:Analgesics; D004338:Drug Combinations; D008024:Ligands; D009842:Oligopeptides; D043562:Receptors, G-Protein-Coupled; D017450:Receptors, Opioid, mu; C105293:endomorphin 1; D000376:Agmatine; D007736:Kynurenic Acid; D000241:Adenosine